22 research outputs found

    Eculizumab improves fatigue in refractory generalized myasthenia gravis

    Get PDF

    Consistent improvement with eculizumab across muscle groups in myasthenia gravis

    Get PDF

    Randomized trial of thymectomy in myasthenia gravis

    Get PDF

    Histoire du livre et de l’imprimé au Canada, Volume II

    No full text
    Entre 1840 et 1918, l’imprimé et le livre, qui avaient déjà contribué à l’élaboration de l’histoire et de l’identité du peuple canadien, deviennent désormais les médias de communication prédominants. Plus que jamais la culture de l’imprimé participe aux transformations qui métamorphoseront la colonie en véritable État, unifiant les peuples qui le composent. C’est cette synergie qui constituera l’un des aspects historiques et culturels les plus fascinants de cette période qui est au centre de ce deuxième volume de l’Histoire du livre et de l’imprimé au Canada. L’expansion du territoire canadien grâce à l’immigration massive, sa traversée par le chemin de fer et par la télégraphie renouvellent entièrement la dynamique de l’imprimé, de Terre-Neuve à Dawson City. Après 1880, l’imprimé de masse voit le jour grâce à la nouvelle technologie qui permet d’imprimer plus rapidement et à moindre coût, et grâce à la constitution de nouveaux marchés desservis par les librairies. Du missel au journal en passant par le livre de recette, le catalogue d’Eaton et l’almanach, les Canadiens sont dorénavant en contact quotidien avec cet objet matériel qu’est l’imprimé. Dans ce contexte, l’auteur émerge lentement, soutenu par un marché de distribution à l’échelle nord-américaine, par un nombre croissant de bibliothèques publiques et par des droits conquis pour la protection de son œuvre et sa diffusion

    The incidence and significance of anti-natalizumab antibodies. Results from the AFFIRM and SENTINEL .

    No full text

    Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

    No full text

    Health-related quality of life in multiple sclerosis: Effects of natalizumab

    No full text
    Objective: To report the relationship between disease activity and health-related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab. Methods: HRQoL data were available from 2,113 multiple sclerosis patients in natalizumab clinical studies. In the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM) study, patients received natalizumab 300mg (n = 627) or placebo (n = 315); in the Safety and Efficacy of Natalizumab in Combination with Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis (SENTINEL) study, patients received interferon beta-la (IFN-\u3b2-1a) plus natalizumab 300mg (n = 589), or IFN-\u3b2-1a plus placebo (n = 582). The Short Form-36 (SF-36) and a subject global assessment visual analog scale were administered at baseline and weeks 24, 52, and 104. Prespecified analyses included changes from baseline to week 104 in SF-36 and visual analog scale scores. Odds ratios for clinically meaningful improvement or worsening on the SF-36 Physical Component Summary (PCS) and Mental Component Summary were calculated. Results: Mean baseline SF-36 scores were significantly less than the general US population and correlated with Expanded Disability Status Scale scores, sustained disability progression, relapse number, and increased volume of brain magnetic resonance imaging lesions. Natalizumab significantly improved SF-36 PCS and Mental Component Summary scores at week 104 in AFFIRM. PCS changes were significantly improved by week 24 and at all subsequent time points. Natalizumab-treated patients in both studies were more likely to experience clinically important improvement and less likely to experience clinically important deterioration on the SF-36 PCS. The visual analog scale also showed significantly improved HRQoL with natalizumab. Interpretation: HRQoL was impaired in relapsing multiple sclerosis patients, correlated with severity of disease as measured by neurological ratings or magnetic resonance imaging, and improved significantly with natalizumab. \ua9 2007 American Neurological Association. Published by Wiley-Liss, Inc

    The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL

    No full text
    corecore